• 1. Enantiomorphic symmetry breaking in crystallization of molten sodium chlorate?
  Martin R. Ward,Gary W. Copeland,Andrew J. Alexander Chem. Commun., 2010,46, 7634-7636
• 2. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 3. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 4. Estimating and correcting interference fringes in infrared spectra in infrared hyperspectral imaging
  Ghazal Azarfar,Ebrahim Aboualizadeh,Nicholas M. Walter,Simona Ratti,Camilla Olivieri,Alessandra Norici,Michael Nasse,Achim Kohler,Mario Giordano Analyst, 2018,143, 4674-4683
• 5. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolidines Phenylpyrrolidines

Comprehensive Overview of (S)-2-(4-Bromophenyl)pyrrolidine hydrochloride (CAS No. 1860947-01-8)

In the rapidly evolving field of pharmaceutical and chemical research, (S)-2-(4-Bromophenyl)pyrrolidine hydrochloride (CAS No. 1860947-01-8) has emerged as a compound of significant interest. This chiral pyrrolidine derivative, characterized by its 4-bromophenyl substitution, is widely utilized in asymmetric synthesis and drug discovery. Its unique structural features make it a valuable intermediate for developing central nervous system (CNS) therapeutics and enzyme inhibitors, aligning with current trends in precision medicine.

The growing demand for enantiomerically pure compounds in modern drug development has spotlighted (S)-2-(4-Bromophenyl)pyrrolidine hydrochloride. Researchers frequently search for "chiral building blocks for drug synthesis" or "pyrrolidine derivatives in medicinal chemistry," reflecting its relevance. The compound's hydrochloride salt form enhances stability and solubility, addressing formulation challenges often encountered in bioavailability optimization—a key focus area in 2024's pharmaceutical R&D.

From a synthetic chemistry perspective, the bromophenyl moiety in CAS 1860947-01-8 enables versatile cross-coupling reactions, particularly in Suzuki-Miyaura and Buchwald-Hartwig transformations. This aligns with industry efforts to develop greener catalytic processes, as evidenced by rising searches for "sustainable bromoarene applications." The compound's (S)-configuration is crucial for stereoselective synthesis, meeting the pharmaceutical industry's need for single-isomer drugs to minimize side effects.

Analytical characterization of (S)-2-(4-Bromophenyl)pyrrolidine hydrochloride typically involves HPLC chiral separation, NMR spectroscopy, and mass spectrometry—techniques frequently queried in scientific databases. Recent publications highlight its potential as a precursor for dopamine receptor ligands, connecting to trending neuroscience research on neurodegenerative disorders. The compound's molecular weight (246.56 g/mol) and pKa properties make it suitable for blood-brain barrier penetration studies, a hot topic in CNS drug design forums.

Quality control specifications for CAS 1860947-01-8 generally require ≥98% chemical purity and >99% enantiomeric excess (ee), parameters critical for reproducibility in high-throughput screening applications. Storage recommendations (2-8°C under inert atmosphere) reflect best practices for amine hydrochloride stability, a common concern among laboratory chemists. These technical details respond to frequent search queries about "handling hygroscopic pharmaceutical intermediates" and "chiral compound storage conditions."

The commercial availability of (S)-2-(4-Bromophenyl)pyrrolidine hydrochloride through specialized fine chemical suppliers supports its adoption in fragment-based drug discovery. Its structural similarity to proline derivatives has sparked interest in peptidomimetic design, particularly for protein-protein interaction inhibitors—an area gaining traction in cancer therapeutics research. This connection addresses frequent searches for "non-peptidic scaffolds in drug design" and "brominated pharmacophores."

Regulatory considerations for CAS 1860947-01-8 focus on REACH compliance and GMP-grade synthesis protocols, reflecting industry priorities for quality assurance in drug development pipelines. The compound's patent landscape reveals applications in kinase inhibitor formulations, coinciding with increased interest in targeted cancer therapies. These aspects respond to commercial researchers' queries about "proprietary intermediates in clinical candidates."

Future research directions for this compound may explore its potential in bioconjugation chemistry or as a template for allosteric modulator development—topics frequently discussed in recent medicinal chemistry symposia. The 4-bromo substituent's versatility for click chemistry modifications positions (S)-2-(4-Bromophenyl)pyrrolidine hydrochloride as a adaptable scaffold for combinatorial libraries, addressing pharmaceutical needs for diverse screening compounds.

• 1189152-82-6((2S)-2-(4-Bromophenyl)pyrrolidine)
• 1187930-57-9(2-(4-bromophenyl)pyrrolidine;hydrochloride)
• 164737-33-1(2-(4-Bromophenyl)-1-methylpyrrolidine)
• 383127-79-5(2-(3-Bromophenyl)pyrrolidine)
• 383127-22-8(2-(4-Bromophenyl)pyrrolidine)
• 1171898-22-8(2-(3-Bromophenyl)pyrrolidine hydrochloride)
• 1391452-66-6((S)-2-(3-Bromophenyl)pyrrolidine hydrochloride)
• 1217632-62-6((2R)-2-(3-Bromophenyl)pyrrolidine)
• 1217694-15-9((2S)-2-(3-bromophenyl)pyrrolidine)
• 1189155-63-2((2R)-2-(4-bromophenyl)pyrrolidine)